Filed in archive
Drugs, Vaccines and Therapeutics
, Genomics, Proteomics and Bioinformatics
by ruth on August 21, 2007

Two Phase III clinical trials involving more than 2000 patients have shown that Novo Nordisk's new anti-diabetes drug candidate liraglutide have a positive effect on blood glucose control, body weight and hypoglycaemia risks. Liraglutide is a once-daily human analogue of the naturally occurring hormone glucagon-Like Peptide-1 (GLP-1), and works by stimulating the release of insulin only when glucose levels become too high. Liraglutide also leads to weight loss instead of weight increase.
In the LEAD® 1 study, liraglutide provided statistically significantly better glucose control than rosiglitazone. Liraglutide treatment led to around 40% of patients reaching the American Diabetes Association goal of HbA1c < 7% at study completion. However, among the patients that had previously been treated with only a single oral antidiabetic drug, liraglutide treatment led to more than 50% of patients reaching this goal.
In the LEAD® 2 study, liraglutide treatment led to an HbA1c improvement that was similar to that observed in the glimepiride-treated group and at the highest dose of liraglutide, more than 40% of patients achieved the HbA1c target of 7%. Among patients previously treated with a single oral antidiabetic drug, close to 65% of the patients on this dose reached the target.
The results of these studies are yet to be published in peer reviewed journals.
Source: Novo Nordisk
Tags:
diabetes
novo+nordisk
proteomics
biotech
liraglutide
drug+candidate
diabetes+drug
anti+diabetes
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/87336
Mr Wong
Vote for Anti-Diabetes Drug Candidate Liraglutide Improves Glucose Control and Lowers Body Weight:
|
Rating: 7.75 out of 4 vote(s) cast.
|
Response from:
universityupdate.com
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







